Skip to content

Triple nuke combination of AZT/3TC/tenofovir below current standards as a first-line regimen

Prezista (darunavir) approved for treatment-experienced patients in Europe

HIV treatment may need to start above 300 CD4s in HIV/hepatitis C coinfected, study suggests

HIV vaccine trials: measurements may overestimate participant understanding

Why did HIV therapy have some benefits for a man with resistance to nearly every antiretroviral?

Severe interaction between low-dose ritonavir and a blood pressure drug observed

Genetic link found with tenofovir-associated kidney problems

Many patients taking efavirez experience long-term CNS side-effects

Kaletra monotherapy: ultra-sensitive tests find viral loads comparable to triple combination therapy